CreatorDB | $47,000,000 | (Sep 17, 2025)
Vega(US) | $65,000,000 | (Sep 17, 2025)
Eve Security | $3,000,000 | (Sep 17, 2025)
Certified by Founder
Lodge
Delphia Therapeutics
start up
United States
- Cambridge, Massachusetts
- 07/05/2024
- Series A
- $67,000,000
Delphia Therapeutics is a biotechnology company pioneering activation lethality, a new area of cancer therapeutics that target cancer's surprising vulnerability to oncogene overactivation. Delphia’s activation lethality platform offers the potential for first-in-class targeted cancer medicines that are effective on their own while also combating the emergence of drug resistance to classic targeted therapies.
- Industry Biotechnology Research
- Website https://www.delphiatx.com/
- LinkedIn https://www.linkedin.com/company/delphia-therapeutics/
Ethosphere | $2,500,000 | (Sep 17, 2025)
Trially AI | $4,700,000 | (Sep 17, 2025)
Bubo² | $2,000,000 | (Sep 17, 2025)
AllRock Bio | $50,000,000 | (Sep 17, 2025)
Overmind | $6,000,000 | (Sep 17, 2025)
BIOWEG | $18,970,160 | (Sep 17, 2025)
Plumerai | $8,700,000 | (Sep 17, 2025)
Hiverge | $5,000,000 | (Sep 17, 2025)
uiAgent | $4,600,000 | (Sep 16, 2025)